PROM1 Antibody

1. These findings link iNOS to Notch1 signaling in CD24(+)CD133(+) LCSCs through the activation of TACE/ADAM17. PMID: 30297396
2. Data reveal that pancreatic aldehyde dehydrogenase (ALDH(hi) cells contain a heterogeneous CD133-enriched population with a subset of beta-cell associated markers in the developing pancreas. PMID: 29285988
3. The downregulation of LIPC in HepG2 cells was associated with decreased CD133 expression, reduced cell proliferation and colony formation, and increased resistance to chemotherapy. PMID: 30015857
4. The expression of CD133 protein in patients with osteosarcoma was significantly elevated and correlated with distant metastasis, potentially serving as a predictive biomarker for poor prognosis in osteosarcoma patients. PMID: 29970672
5. This study demonstrates a significant correlation between CD133 expression and differentiation of NSCLC, both in the presented results and pooled previous findings. Based on current data, CD133 may hold prognostic significance for patients with NSCLC. PMID: 29758924
6. CD133 downregulation also suppressed iRFA-induced cell viability, invasion, and autophagy. Collectively, these findings indicate that RFA may promote residual HCC cell progression through an autophagy and CD133 feedback loop. PMID: 29749472
7. CD133 staining was positive in 17.9% of colorectal adenomas. Furthermore, CD133 expression was associated with differentiation status (p = 0.003) and tumor size (p = 0.03). PMID: 28190751
8. CD133 expression and MYCN amplification induce chemoresistance and reduce average survival time in pediatric neuroblastoma. PMID: 29322842
9. Negative CD133 expression was an independent risk factor for reduced disease-free survival in colon cancer with peritoneal metastasis. PMID: 29328371
10. This meta-analysis indicated that both CD133 and Nestin expression were significantly associated with advanced FIGO stage and larger size of residual cancer in EOC patients. PMID: 29168665
11. Cytoplasmic and nuclear CD133 expression in colorectal adenocarcinoma cells and tumor microenvironment cells may play a crucial role in early colorectal adenocarcinoma carcinogenesis, while decreased CD133 nuclear expression in colorectal adenocarcinoma cells may contribute to colorectal adenocarcinoma metastasis. PMID: 30061254
12. CD133 expression may serve as a biomarker for early detection of gastric cancer. PMID: 30061208
13. Human UCB- CD133(+) hematopoietic stem cells are remarkably potent cell candidates for transdifferentiation into motor neuron-like cells, in vitro. PMID: 28754612
14. This study confirms that the CD133lo subset of Rb Y79 cell line possesses characteristics of cancer stem cells, as demonstrated by in vitro functional assays, aligning with previous findings in primary Rb tumors. PMID: 29162051
15. The expression of CD133 and SSEA4 determines the differentiation fate of pluripotent cancer stem cells. PMID: 28624968
16. CD133 is a valuable predictive or prognostic biomarker for Colorectal cancer in clinical assessment and may serve as a potential therapeutic target for Colorectal cancer. PMID: 29879012
17. Bmi1 promoted invasion and migration of CD133+Hep G2 cells. PMID: 28849237
18. Lymph node metastasis is strongly associated with the expression status of HGF and CD133 at the deep invasive front, suggesting their usefulness as independent predictive markers of lymph node metastasis in early gastric cancer. PMID: 28595915
19. Higher hazard ratios for associations between CD133 rs2240688 polymorphism and overall survival (OS) were observed in patients with adjuvant chemotherapy and radiotherapy for curative intent. The study confirmed the significant association between the SNP rs2240688 A>C of CD133 and OS of non-small cell lung cancer patients. PMID: 28827262
20. glioma cells expressing CD133 are capable of modulating tumor microenvironment through the IL-1beta signaling pathway. PMID: 28736425
21. Exogenous CXCL3 induced Erk1/2 and ETS1 phosphorylation and promoted CD133 expression. PMID: 27255419
22. Low expressions of Oct4-EpCAM in IHC and CD133 in qPCR may reveal roles in gastric cancer. PMID: 27557490
23. The clinical evidence revealed that cytoplasmic CD133 expression was correlated with poor prognosis, while nuclear CD133 expression was significantly correlated with favorable prognosis. PMID: 28687090
24. High CD133 expression is associated with Basal Breast Cancers. PMID: 28216417
25. In conclusion, p-STAT3 may participate in the progression of the early stage of colon cancer through the up-regulation of CD133, which in turn induces survivin expression. However, the regulatory mechanism of these molecules in tumor progression in vivo requires further investigation. PMID: 29432737
26. Circulating tumor cells expressing cytokeratin and tumor-initiating cell markers, including ALDH, CD133, and CD44, were identified in patients with pancreatic adenocarcinoma. These TIC-like CTCs were associated with poor prognosis after surgical resection and an increased incidence of tumor recurrence. PMID: 27789528
27. High CD133 expression is associated with renal cell carcinoma. PMID: 27588469
28. CD133+CD24lo phenotype defines 5-FU-resistant human colon cancer stem cell-like cells. PMID: 27659530
29. Intraperitoneal enrichment of cancer stem-like cells, from ovarian cancer cell lines or primary ovarian tumor, provides a rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers. PMID: 27655682
30. CD133 may have different roles in survival from non-small-cell lung cancer based on ethnic groups [meta-analysis]. PMID: 27489355
31. Notch1 signaling plays a significant role in the maintenance of the cancer stem-like phenotype in diffuse type gastric cancer through an RBP-Jkappa dependent pathway; inhibiting Notch1 signaling could be an effective therapy against CD133 positive diffuse type gastric cancers. PMID: 27489358
32. Low CD133 Expression is associated with Recurrence in Colorectal Cancer with Synchronous Liver Metastasis. PMID: 26832881
33. CD133+ cells were genetically heterogeneous among patients without any defined profile compared to CD133-/EpCAM+ cells. PMID: 28347289
34. Results show that CD133 and MDR1 expression increase in recurrent pediatric pilocytic astrocytomas (PAs) following chemotherapy, and in drug resistant tumor cells. CD133 regulates MDR1 expression via the PI3K/AKT/NF-kappaB signaling. These results provide evidence that CD133 contributes to multidrug resistance by regulating MDR1 levels via the PI3K-Akt-NF-kappaB signal pathway. PMID: 28137267
35. CD133(+) CD44(+) CD54(+) cellular subpopulation of circulating tumor cells has a prognostic value in colorectal cancer patients with liver metastasis, especially in the survival of CRC patients with liver metastasis who did not undergo surgical treatment for metastasis. PMID: 29105339
36. High CD133 expression is associated with radioresistance in liver cancer. PMID: 26993601
37. CD133+ glioblastoma cells express molecular signatures of MSCs, neural stem cells, and pluripotent stem cells. PMID: 27244897
38. These findings indicate a novel potential anti-tumor mechanism for tubacin in CD133-expressing malignancies. PMID: 28452069
39. CD133 expression in colonic liver metastases is a negative prognostic factor for disease-free survival after liver resection. PMID: 29277789
40. The study found a significant association between the SNP rs2240688A[C of CD133 and lung cancer risk. PMID: 27130457
41. Results strongly indicate functional roles for CD133 in reactive oxygen species defense and in evading anticancer therapies in hepatocellular carcinoma. PMID: 28253902
42. High CD133 expression is associated with clear cell renal cell carcinoma. PMID: 29050853
43. This study described three cases in which variations in the PROM1 gene may play a role in the pathogenesis of macular dystrophy or be associated with both autosomal recessive and autosomal dominant inheritance. PMID: 28095140
44. CD133 polymorphisms are promising biomarkers for genetic susceptibility and prognosis prediction of gastric cancer. PMID: 28326835
45. Low CD133 expression is associated with gastric cancer. PMID: 28218426
46. Our results strongly suggest epigenetic regulation of CD133 expression by promoter methylation in gastrointestinal stromal tumors. PMID: 28398518
47. Taken together, these findings show that elevated levels of CD133 lead to Oral squamous cell carcinoma (OSCC) invasiveness and metastasis, associated with the upregulation of EMT and stemness markers. PMID: 27137188
48. CD133 and CD44 in glioblastoma stem cells have roles in cell proliferation, phenotype stability, and intra-tumor heterogeneity. PMID: 28241049
49. The combination of CD133 phenotyping and World Health Organization grading may assist in stratifying patients with well-differentiated pancreatic neuroendocrine tumors. PMID: 27864124
50. CD133 facilitates cancer stem cell-like properties by stabilizing EGFR-AKT signaling in HCC. PMID: 28034805

Show More

Hide All

HGNC: 9454

OMIM: 603786

KEGG: hsa:8842

STRING: 9606.ENSP00000415481

UniGene: Hs.614734